Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Eerder inzicht in effectiviteit nieuw geneesmiddel bij maagkanker
nov 2023 | Maag-darm-leveroncologie